Teva Pharmaceutical Industries Investor Presentation — May 2017

Document content

Teva Pharmaceutical Industries Ltd.

First Quarter 2017 Results

Cautionary Note Regarding Forward -Looking Statements

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward -looking statements .

Important factors that could cause or contribute to such differences include risks relating to:

• our generics medicines business, including : that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals

business (“Actavis Generics”) ; our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics ; the increase in the number of

competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products ; price erosion relating to our generic products, both from competing products and as a result

of increased governmental pricing pressures ; and our ability to take advantage of high -value biosimilar opportunities ;

• our specialty medicines business, including : competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and

orally -administered alternatives ; our ability to achieve expected results from investments in our product pipeline ; competition from companies with greater resources and capabilities ; and the effectiveness of our

patents and other measures to protect our intellectual property rights ;

• our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may

result in a downgrade of our credit ratings ;

• our business and operations in general, including : uncertainties relating to our recent senior management changes ; our ability to develop and commercialize additional pharmaceutical products ; manufacturing or

quality control problems, which may damage our reputation for quality production and require costly remediation ; interruptions in our supply chain ; disruptions of our or third party information technology systems or